What Artelac Splash MDO treats: main uses and benefits

The therapeutic role of this solution is consistent with the established use of ophthalmic lubricants for managing eye dryness and irritation.

This product is applied in clinical and everyday settings to help address symptom clusters associated with pronounced dryness. It is relevant for managing certain distressing manifestations such as burning, scratchiness, and the sensation of a foreign body in the eye. It is commonly used across conditions presenting with episodic or fluctuating symptom patterns, including those linked to environmental exposure or extended visual strain. The solution supports symptomatic relief, which may assist patients with managing difficult episodes of discomfort and contributes to easing the overall symptom load. Use is relevant when symptoms become more noticeable due to external stress. The product supports general comfort when symptoms become more noticeable, and may assist with maintaining routine stability.

Summary of Therapeutic Focus

Focus Area	Symptom Relief	Common Context
Primary Domain	Ocular Surface Discomfort	Periods of long-term dryness
Key Symptoms	Burning, Scratchiness, Grittiness	Computer use, Air-conditioned environments
Supportive Use	Contact lens rewetting	Post-operative symptom management

Regulatory References

1. NIH DailyMed overview of Ophthalmic Lubricants

Who Can and Cannot Use Artelac Splash MDO?

The population eligibility for Artelac Splash MDO is defined by regulatory documentation focusing on local ocular integrity and sensitivity to its components.

---

Eligibility Scope

Classification	Regulatory Statement
Populations Allowed	General adult population; Contact lens wearers (suitable for use with soft and hard lenses).
Age-Related Rules	No specific minimum age restriction is documented, indicating suitability for children, adults, and older adults.
Contraindication	Must not be used by patients with a known hypersensitivity (allergy) to Sodium Hyaluronate or any of the solution's excipients.
Conditional Restriction	Use with caution if the patient has severe damage to the cornea; this is due to the phosphate content, which is rarely associated with calcium deposits on a severely damaged cornea.
Systemic Conditions	No restrictions are documented for conditions like hepatic or renal impairment.
Pregnancy/Lactation	No explicit regulatory statement is provided as to whether use is permitted or restricted.

---

Resulting Eligibility Structure

Official regulatory documents define a broad eligible population for Artelac Splash MDO, primarily excluding individuals with allergies. Use is explicitly permitted for contact lens wearers, and there are no stated age-based restrictions. The only conditional caution relates to pre-existing severe corneal damage.

Interactions with other medicines and products

The interaction profile for this ophthalmic lubricant is specifically focused on the administration of other topical products, as regulatory data confirm a negligible risk of systemic interactions.

Documented Topical and Timing Interactions

Interaction Type	Interaction Entity	Regulatory Outcome or Restriction
Topical Incompatibility	Quaternary Ammonium Compounds	Co-use is restricted due to a documented risk of physical precipitation of the active ingredient.
Administration Timing	Other Topical Ophthalmic Products	Administration requires a mandatory separation time to prevent the modification of the co-administered drug's effects.

Official prescribing information mandates a specific interval between applications: the solution must be administered at least 15 minutes apart from any other eye product. This timing rule addresses the potential for the co-administered product to have its intended effects altered on the ocular surface. Regulatory documentation also affirms that no clinically significant interactions are documented concerning systemic metabolic pathways, such as those involving cytochrome P450 enzymes or drug transporters, due to the minimal systemic absorption of the active ingredient.

Artelac Splash MDO is an aqueous solution containing 0.2% Hyaluronic Acid (HA). The mechanism is predicated on the viscoelastic properties of this high molecular weight biopolymer, which facilitates the effective binding of water molecules to the epithelial surface of the eye.

The formulation creates a viscoelastic layer with high surface retention over the corneal and conjunctival epithelia. This physical layer functions to augment the thickness of the aqueous layer, thereby increasing the tear film break-up time (TFBUT). The presence of the HA layer on the epithelial surface reinforces the corneal interface, facilitates blinking by providing lubrication, and promotes the prolonged retention of moisture on the ocular surface. The system-level physiological modulation is strictly limited to the creation of a physical layer that alters the properties of the tear film and reduces the friction coefficient between the palpebral and bulbar conjunctiva.

Administration Procedure

Artelac Splash MDO is designed for ease of use via a multi-dose pump system. To ensure proper application and maintain the integrity of the solution, the following steps are typically observed:

Preparation

Before using the product, wash hands thoroughly with soap and water. Remove the protective cap from the tip of the bottle before each use. For the first application, or if the bottle has not been used for some time, it may be necessary to prime the mechanism by pumping the bottle several times until the first drop appears.

Application

1. Hold the bottle as instructed by the manufacturer, typically with the thumb on the ergonomic support and other fingers at the base.
2. Tilt the head back slightly and gently pull the lower eyelid down with a free finger to create a small pocket.
3. Hold the bottle vertically over the eye. Avoid any contact between the tip of the bottle and the fingers, the surface of the eye, or the eyelashes to prevent contamination.
4. Apply firm pressure to the pump mechanism to release a single drop into the eye.
5. Close the eye slowly and move it in all directions to distribute the liquid evenly across the ocular surface.

After Use

Immediately replace the protective cap onto the tip of the bottle to keep it clean. Due to the design of the pump system, a small amount of solution may remain on the tip; this should be shaken off if necessary, but the tip should not be wiped or touched.

Use with Contact Lenses

This solution is compatible with both soft and rigid contact lenses. It can be applied while wearing lenses to rehydrate them and improve comfort throughout the day. It is not necessary to remove the lenses prior to application.

The research base for Artelac Splash MDO, focusing on its active component Sodium Hyaluronate, centers on Randomized Controlled Trials (RCTs). These studies examined how symptoms change over time in adult patients diagnosed with Dry Eye Disease (DED), including individuals with varying symptom severity. Research investigated changes in patient-reported experiences, such as the sensation of burning, scratchiness, or the feeling of a foreign body in the eye.

Studies monitored changes in tear film stability, often measured by Tear Break-Up Time (TBUT), and explored damage to the corneal surface through the use of staining scores. This evidence contributes to understanding symptom patterns for conditions characterized by fluctuating manifestations of dryness. The overall consistency of evidence from multiple trials and systematic reviews is generally labeled as Moderate by researchers.

Specific research has also explored the solution's use in the context of temporary physiological imbalance following certain surgical procedures, such as cataract surgery. These studies are typically conducted over short-term assessments, often two to four weeks, with some intermediate follow-up extending up to three months.

The evidence landscape still contains key limitations. Many studies relied on relatively small sample sizes, and follow-up durations were limited, meaning that long-term effects are not fully established. Furthermore, certainty remains low regarding the differences in patterns observed between Sodium Hyaluronate and other common polymer-based artificial tears; comparative evidence is limited for clarity in this area. Results apply only to the adult populations studied.

Key Studies & References

1. Sodium hyaluronate in the treatment of dry eye after cataract surgery: a meta-analysis
2. Evaluation of Dry Eye Treatment with Sodium Hyaluronate- and Dexpanthenol-Containing Eye Drops on Ocular Surface Improvement after Cataract Surgery

Common questions about Artelac Splash MDO (FAQ)

---

Q: What is the consistency of Artelac Splash MDO compared to other eye drops?

A: Official product information indicates that Artelac Splash MDO has viscoelastic properties due to its 0.24% Sodium Hyaluronate content. This means the solution is designed to be slightly thicker than simple water-like drops. This characteristic is intended to help the solution spread easily and remain on the eye surface for longer periods to provide continuous hydration.

Q: What does 'immediate moisture' mean for this product?

A: The product's mechanism of action is designed with the intent of providing immediate relief from symptoms of dryness. This is attributed to the 0.24% hyaluronic acid active ingredient quickly facilitating the restoration of hydration soon after application to the eye's surface.

Q: Has Artelac Splash MDO been tested on children?

A: Official safety labeling states the product is suitable for use by children. However, the formal Randomized Controlled Trials (RCTs) that form the core evidence base for the product were primarily conducted on adult populations. Information about the product's use in children is based on its established safety profile and general suitability.

Q: Is the bottle design of Artelac Splash MDO different from single-dose units?

A: Artelac Splash MDO uses a Multi-Dose Ophthalmic (MDO) pump system, which is different from single-use ampules. The MDO pump is designed to be ergonomic and features a specific thumb rest. This design allows for repeated sterile applications from a single bottle.

Q: Is this product approved by the FDA or a similar major regulatory body?

A: Regulatory documents confirm that the product is manufactured and regulated as a medical device in several international jurisdictions. Its classification as a medical device confirms its registration by official governmental bodies in the markets where it is available.

Q: What is the scientific classification of Artelac Splash MDO (e.g., medical device, drug)?

A: According to regulatory filings in various jurisdictions, Artelac Splash MDO is classified as a medical device.

Q: Does Artelac Splash MDO contain any ingredients derived from animals?

A: The active ingredient, Sodium Hyaluronate, is described as a biological polymer found naturally in the human body. While the ingredient itself is a naturally occurring substance, regulatory documents do not provide information on the specific commercial source (e.g., animal or non-animal origin) used in the product's manufacturing.

Q: How does the preservation system of the MDO bottle work?

A: The Multi-Dose Ophthalmic (MDO) pump system uses a specialized mechanism to keep the solution sterile and prevent microbial contamination. This design means the product is entirely preservative-free while still being usable for up to six months after the bottle is first opened.

Q: Why is this product called 'MDO'?

A: 'MDO' is an acronym that stands for Multi-Dose Ophthalmic system. This term identifies the specific pump technology used, which allows the bottle to dispense many doses while ensuring the solution remains sterile and completely preservative-free.

Q: Do I need a prescription to buy Artelac Splash MDO?

A: The product is typically classified as an over-the-counter (OTC) item in many regulated markets. This means it can usually be purchased without a prescription.

Q: Can Artelac Splash MDO be used for red eyes?

A: Official indications state that the product is intended for the relief of symptoms related to dry eyes, including dryness, irritation, and fatigue. There is no specific regulatory statement or claim that links the product directly to the treatment of red eyes alone.

Q: Do I need to wait after using other eye products, like washes or hygiene solutions?

A: Official prescribing information mandates that the product must be administered at least 15 minutes apart from any other topical product, including eye washes or eyelid hygiene solutions, to prevent potential modification of its effects on the ocular surface.

Q: What is the maximum duration I can continuously use Artelac Splash MDO?

A: According to regulatory documents, there is no limitation on the duration of use for Artelac Splash MDO. The product is designed to be used every day and whenever needed to provide continuous lubrication. The main safety requirement is to discontinue use if irritation becomes persistent or worsens.

Q: Is Artelac Splash MDO oil-based or water-based?

A: The solution is classified as an aqueous solution, meaning it is water-based. Its primary components are sterile water, the active ingredient Sodium Hyaluronate, and essential stabilizing salts. The formulation is not oil-based.

Q: Is the product sterile when first opened?

A: Yes, the product is intended to be sterile upon opening. This is ensured because the solution is prepared using sterile water and is dispensed via a specialized Multi-Dose Ophthalmic (MDO) pump system that maintains sterility without the use of preservatives.

Q: Are there different concentrations of the main ingredient available?

A: The Artelac Splash MDO product contains 0.24% Sodium Hyaluronate. Regulatory documentation indicates that related products in the Artelac line, such as the single-dose units, may be formulated with a slightly different concentration of the same active ingredient.

Q: Is Artelac Splash MDO formulated for daytime or nighttime use?

A: The product is designed for general use and for application as required throughout the day. Other products within the Artelac line may be specifically formulated for nighttime use.

Q: Where is the Artelac Splash MDO product manufactured?

A: Official manufacturer information states that Artelac Splash MDO is produced by Bausch & Lomb. The manufacturing location is listed as Dr. Gerhard Mann GmbH, located in Germany.

Q: Can Artelac Splash MDO be stored in the refrigerator?

A: Official storage requirements mandate that the product be stored at a temperature not exceeding 25 C. While refrigeration is not a specified requirement, storing it at or below this temperature limit helps maintain the product's integrity. Freezing the solution should be avoided.

Q: Is the drop size consistent from the MDO bottle?

A: The product is dispensed through a specialized Multi-Dose Ophthalmic (MDO) pump system. This system is specifically designed to control the dosage. The design of this system is intended to provide a controlled and consistent dosage with each application.

Q: What is the osmolality of Artelac Splash MDO?

A: The solution is officially described as isotonic with the natural tear film. The term isotonic means the salt and water balance of the solution is designed to match that of natural tears. While the specific numerical osmolality value is not listed in general regulatory documents, this characteristic is intended to support its compatibility with the eye.

Q: Can I share my Artelac Splash MDO bottle with another person?

A: Official safety precautions specify that Artelac Splash MDO is strictly for individual use only.

Artelac Splash MDO Storage and Disposal: Regulatory Profile

The official regulatory documents specify mandatory storage and disposal rules for Artelac Splash MDO.

Item	Official Regulatory Requirement
Labeled storage temperature requirements	Store the product at a temperature not exceeding 25 C.
Stability after opening/reconstitution	The solution is usable for up to 6 months (24 weeks) after the bottle is first opened.
Handling requirements	Avoid touching the eye with the tip of the container to prevent contamination.
Disposal instructions	Do not throw away any medicines via wastewater or household waste. Ask the pharmacist how to dispose of medicines no longer required.
Child-protection storage requirements	The product must be kept out of reach of children.

Official instructions require the product be stored at or below 25 C and establish a fixed stability period of 6 months after opening. Handling rules mandate preventing contamination of the tip. Disposal instructions prohibit discarding the medicine through wastewater or household trash, requiring that it be returned to a pharmacist for appropriate handling, which helps to protect the environment.